BidaskClub cut shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a buy rating to a hold rating in a report issued on Tuesday.

A number of other equities analysts have also commented on the stock. credit lowered shares of Ultragenyx Pharmaceutical from an outperform rating to a neutral rating and raised their price objective for the stock from $67.00 to $80.00 in a research note on Thursday, June 21st. Credit Suisse Group lowered shares of Ultragenyx Pharmaceutical from an outperform rating to a neutral rating and raised their price objective for the stock from $67.00 to $80.00 in a research note on Thursday, June 21st. They noted that the move was a valuation call. Leerink Swann raised their price objective on shares of Ultragenyx Pharmaceutical from $68.00 to $95.00 and gave the stock an outperform rating in a research note on Tuesday, July 17th. Morgan Stanley reaffirmed an equal weight rating and issued a $92.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Monday, September 10th. Finally, JMP Securities reaffirmed a buy rating and issued a $94.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Sunday, September 2nd. Six investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Ultragenyx Pharmaceutical has an average rating of Buy and a consensus price target of $85.53.

Ultragenyx Pharmaceutical stock opened at $64.74 on Tuesday. The company has a market capitalization of $3.83 billion, a price-to-earnings ratio of -8.63 and a beta of 1.95. Ultragenyx Pharmaceutical has a 1 year low of $41.67 and a 1 year high of $90.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.08) by $1.02. The firm had revenue of $12.79 million for the quarter, compared to analyst estimates of $5.63 million. Ultragenyx Pharmaceutical had a negative net margin of 703.27% and a negative return on equity of 44.09%. During the same quarter in the previous year, the business posted ($1.72) earnings per share. Equities analysts forecast that Ultragenyx Pharmaceutical will post -4.4 EPS for the current year.

In other Ultragenyx Pharmaceutical news, CFO Shalini Sharp sold 6,700 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $90.07, for a total transaction of $603,469.00. Following the completion of the sale, the chief financial officer now owns 56,828 shares of the company’s stock, valued at approximately $5,118,497.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William Aliski sold 3,750 shares of Ultragenyx Pharmaceutical stock in a transaction on Wednesday, August 8th. The shares were sold at an average price of $76.66, for a total transaction of $287,475.00. Following the sale, the director now directly owns 72,610 shares of the company’s stock, valued at approximately $5,566,282.60. The disclosure for this sale can be found here. Insiders have sold a total of 35,000 shares of company stock valued at $2,700,774 in the last three months. Company insiders own 8.40% of the company’s stock.

Several large investors have recently modified their holdings of RARE. Advisors Asset Management Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at $181,000. Hsbc Holdings PLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter valued at $213,000. Xact Kapitalforvaltning AB boosted its stake in shares of Ultragenyx Pharmaceutical by 49.7% during the 1st quarter. Xact Kapitalforvaltning AB now owns 6,623 shares of the biopharmaceutical company’s stock valued at $338,000 after buying an additional 2,200 shares during the period. JBF Capital Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at $384,000. Finally, Strs Ohio boosted its stake in shares of Ultragenyx Pharmaceutical by 358.3% during the 2nd quarter. Strs Ohio now owns 5,500 shares of the biopharmaceutical company’s stock valued at $422,000 after buying an additional 4,300 shares during the period. 96.09% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Further Reading: Hedge Funds – Risk or Reward?

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.